IN2014MN02127A - - Google Patents

Info

Publication number
IN2014MN02127A
IN2014MN02127A IN2127MUN2014A IN2014MN02127A IN 2014MN02127 A IN2014MN02127 A IN 2014MN02127A IN 2127MUN2014 A IN2127MUN2014 A IN 2127MUN2014A IN 2014MN02127 A IN2014MN02127 A IN 2014MN02127A
Authority
IN
India
Prior art keywords
compounds
calcium
crac
channel
formula
Prior art date
Application number
Inventor
Nageswara Rao Irlapati
Gokul Keruji Deshmukh
Nilesh Raghunath Khedkar
Kiran Chandrashekhar Kulkarni
Zubair Abdul Wajid Shaikh
Neelima Sinha
Venkata P Palle
Rajender Kumar Kamboj
Original Assignee
Lupin Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lupin Ltd filed Critical Lupin Ltd
Priority to IN2127MUN2014 priority Critical patent/IN2014MN02127A/en
Publication of IN2014MN02127A publication Critical patent/IN2014MN02127A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention relates to compounds described herein Formula (I) and pharmaceutical acceptable salts thereof which modulate the activity of calcium release activated calcium (CRAC) channel. The invention also describes the compounds of Formula (I) and pharmaceutical compositions containing such compounds thereof for treating managing and/or lessening the severity of diseases disorders syndromes or conditions associated with the modulation of calcium release activated calcium (CRAC) channel.
IN2127MUN2014 2012-05-02 2013-05-01 IN2014MN02127A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
IN2127MUN2014 IN2014MN02127A (en) 2012-05-02 2013-05-01

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
IN6KO2012 2012-05-02
IN1474KO2012 2012-12-28
PCT/IB2013/053446 WO2013164773A1 (en) 2012-05-02 2013-05-01 Substituted pyrazole compounds as crac modulators
IN2127MUN2014 IN2014MN02127A (en) 2012-05-02 2013-05-01

Publications (1)

Publication Number Publication Date
IN2014MN02127A true IN2014MN02127A (en) 2015-09-11

Family

ID=48428566

Family Applications (1)

Application Number Title Priority Date Filing Date
IN2127MUN2014 IN2014MN02127A (en) 2012-05-02 2013-05-01

Country Status (7)

Country Link
US (2) US9409898B2 (en)
EP (1) EP2844656A1 (en)
AU (1) AU2013255441B2 (en)
CA (1) CA2871222A1 (en)
IN (1) IN2014MN02127A (en)
WO (1) WO2013164773A1 (en)
ZA (1) ZA201407668B (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015197188A1 (en) * 2014-06-24 2015-12-30 Grünenthal GmbH Pyrazolyl-based carboxamides as crac inhibitors
WO2015197187A1 (en) * 2014-06-24 2015-12-30 Grünenthal GmbH Pyrazolyl-based carboxamides v
WO2016187182A1 (en) 2015-05-18 2016-11-24 Beth Israel Deaconess Medical Center, Inc. Substance p, mast cell degranulation inhibitors, and peripheral neuropathy
AU2019340601A1 (en) 2018-09-14 2021-05-13 Rhizen Pharmaceuticals A G Compositions comprising a CRAC inhibitor and a corticosteroid and methods of use thereof
US11034669B2 (en) 2018-11-30 2021-06-15 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof
US20220235005A1 (en) 2019-06-06 2022-07-28 Basf Se Fungicidal n-(pyrid-3-yl)carboxamides
CN110604735B (en) * 2019-09-18 2022-10-25 华东师范大学 Compound for treating hepatic fibrosis and scleroderma and application thereof
WO2021063735A1 (en) 2019-10-02 2021-04-08 Basf Se New bicyclic pyridine derivatives

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU751139B2 (en) * 1997-10-13 2002-08-08 Astellas Pharma Inc. Amide derivative
JP2002510679A (en) 1998-04-08 2002-04-09 アボット・ラボラトリーズ Pyrazole cytokine production inhibitor
AU4229999A (en) * 1998-06-05 1999-12-20 Boehringer Ingelheim Pharmaceuticals, Inc. Substituted 1-(4-aminophenyl)pyrazoles and their use as anti-inflammatory agents
DE602004030689D1 (en) 2003-07-23 2011-02-03 Synta Pharmaceuticals Corp COMPOUNDS AGAINST INFLAMMATION AND IMMUNE-RELEVANT USES
US7709518B2 (en) 2004-09-21 2010-05-04 Synta Pharmaceuticals Corp. Compounds for inflammation and immune-related uses
AU2006211646B2 (en) 2005-01-07 2012-09-20 Synta Pharmaceuticals Corp. Compounds for inflammation and immune-related uses
AU2006208045B2 (en) 2005-01-25 2012-08-30 Synta Pharmaceuticals Corp. Compounds for inflammation and immune-related uses
WO2006081389A1 (en) 2005-01-25 2006-08-03 Synta Pharmaceuticals Corp. Thiophene compounds for inflammation and immune-related uses
CA2639927A1 (en) 2006-01-25 2007-08-02 Synta Pharmaceuticals Corp. Substituted biaryl compounds for inflammation and immune-related uses
AU2007208227A1 (en) 2006-01-25 2007-08-02 Synta Pharmaceuticals Corp. Phenyl and pyridyl compounds for inflammation and immune-related uses
TW200806641A (en) 2006-01-25 2008-02-01 Synta Pharmaceuticals Corp Substituted aromatic compounds for inflammation and immune-related uses
DK1984338T3 (en) 2006-01-31 2013-04-22 Synta Pharmaceuticals Corp Pyridylphenyl compounds for inflammation and immune-related applications
WO2009017819A1 (en) 2007-08-01 2009-02-05 Synta Pharmaceuticals Corp. Pyridine compounds for inflammation and immune-related uses
MX2010002712A (en) 2007-09-10 2010-06-09 Calcimedica Inc Compounds that modulate intracellular calcium.
US8389567B2 (en) 2007-12-12 2013-03-05 Calcimedica, Inc. Compounds that modulate intracellular calcium
BRPI0917719A2 (en) 2008-08-27 2019-11-19 Calcimedica Inc intracellular calcium modulating compounds
US8524763B2 (en) 2008-09-22 2013-09-03 Calcimedica, Inc. Inhibitors of store operated calcium release
EP2350006A1 (en) 2008-10-01 2011-08-03 Synta Pharmaceuticals Corp. Compounds for inflammation and immune-related uses
EP2477982A4 (en) 2009-09-16 2013-04-03 Calcimedica Inc Compounds that modulate intracellular calcium
US8377970B2 (en) 2009-10-08 2013-02-19 Rhizen Pharmaceuticals Sa Modulators of calcium release-activated calcium channel
CA2806634A1 (en) 2010-08-20 2012-02-23 Gruenenthal Gmbh Substituted cyclic carboxamide and urea derivatives as ligands of the vanilloid receptor
JP5387541B2 (en) 2010-10-29 2014-01-15 住友電装株式会社 Grommet
PL2632906T3 (en) * 2010-10-30 2016-09-30 Oxazoline and isoxazoline derivatives as crac modulators
EP2638034A1 (en) 2010-11-10 2013-09-18 Grünenthal GmbH Substituted heteroaromatic carboxamide and urea derivatives as vanilloid receptor ligands
EP2704701B1 (en) 2011-05-03 2018-01-03 PRCL Research Inc. Compounds for inflammation and immune-related uses
EP2768810A1 (en) 2011-10-19 2014-08-27 Calcimedica, Inc. Compounds that modulate intracellular calcium
US9856240B2 (en) 2011-10-19 2018-01-02 Calcimedica, Inc. Compounds that modulate intracellular calcium

Also Published As

Publication number Publication date
WO2013164773A1 (en) 2013-11-07
AU2013255441A1 (en) 2014-11-13
EP2844656A1 (en) 2015-03-11
ZA201407668B (en) 2015-11-25
AU2013255441B2 (en) 2017-11-09
US20150111925A1 (en) 2015-04-23
CA2871222A1 (en) 2013-11-07
US20160304507A1 (en) 2016-10-20
US9409898B2 (en) 2016-08-09

Similar Documents

Publication Publication Date Title
IN2014MN02126A (en)
IN2014MN02127A (en)
CO6430427A2 (en) BENZOFURANILO DERIVATIVES
TN2013000348A1 (en) Compounds and compositions as trk inhibitors
PH12015500551A1 (en) Tricyclic quinoline and quinoline derivatives
GEP20166438B (en) Imidazopyrrolidinone compounds
PH12014502757B1 (en) Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
CR20110103A (en) HETEROARILOS SUBSTITUTED
IN2014CN04907A (en)
MX2015012478A (en) Methods and compositions for inhibition of bromodomain-containing proteins.
MD20140109A2 (en) Indole and indazole compounds that activate AMPK
IN2012DN00943A (en)
WO2012170931A3 (en) Compounds that modulate intracellular calcium
MX337711B (en) Compounds that modulate intracellular calcium.
MY162689A (en) Oxazoline and isoxazoline derivatives as crac modulators
TN2013000346A1 (en) Asymmetric ureas and medical uses thereof
EA026940B9 (en) Substituted chroman compounds as calcium sensing receptor modulators
WO2012170951A3 (en) Compounds that modulate intracellular calcium
TW201613878A (en) Pyrazine GPR40 agonists for the treatment of type II diabetes
AU2011322715A8 (en) Treatment of MeCP2-associated disorders
UY36081A (en) METALOENZYME INHIBITING COMPOUNDS AS FUNGICIDES.
PH12014501979A1 (en) Fused bicyclic 2,4-diaminopyrimidine derivative as a dual alk and fak inhibitor
IN2015MN00421A (en)
MX357828B (en) Compositions comprising plasma growth factors for use in the treatment of neurodegenerative disorders.
WO2013175347A3 (en) Compositions and methods for treatment of respiratory disorders